和黄医药(00013.HK):治疗肾细胞癌联合疗法研究达主要终点

阿斯达克财经
19 Mar

和黄医药(00013.HK) 信达生物(01801.HK) 联合公布,呋喹替尼和信迪利单抗联合疗法,用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2中国II/III期研究,已达到盲态独立中心阅片根据RECIST 1.1标准评估的无进展生存期的主要终点。
公告指,呋喹替尼和信迪利单抗的联合疗法,早前已基于FRUSICA-1研究的数据取得中国国家药监局附条件批准,用于治疗既往系统性抗肿瘤治疗后失败,且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整的子宫内膜癌患者。(js/w)

(港股报价延迟最少十五分钟。沽空资料截至 2025-03-18 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10